Home » FDA Says Meridia Early Data May Signal Cardiovascular Risk
FDA Says Meridia Early Data May Signal Cardiovascular Risk
November 25, 2009
Healthcare professionals should avoid prescribing Abbott Laboratories’ anti-obesity drug Meridia for patients with a history of cardiovascular events
as preliminary data suggest patients taking the drug have a higher number of adverse events including heart attack, stroke and death.